ELIZABETH SHPALL to Interleukin 1 Receptor Antagonist Protein
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Interleukin 1 Receptor Antagonist Protein.
Connection Strength
0.263
-
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023 11 14; 7(21):6785-6789.
Score: 0.219
-
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020 07 14; 4(13):3123-3127.
Score: 0.043